Oak Ridge Investments’s UroGen Pharma URGN Stock Holding History

Oak Ridge Investments’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.26M	Buy	88,591 +2,188	+3%	+$59.3K	0.18%	82
2026 Q1	$1.55M	Buy	86,403 +1,173	+1%	+$23.5K	0.1%	106
2025 Q4	$2M	Sell	85,230 -2,277	-3%	-$49.4K	0.12%	93
2025 Q3	$1.75M	Buy	87,507 +16,937	+24%	+$304K	0.11%	98
2025 Q2	$967K	Sell	70,570 -3,134	-4%	-$30.1K	0.07%	115
2025 Q1	$815K	Buy	73,704 +12,539	+21%	+$134K	0.07%	122
2024 Q4	$651K	Sell	61,165 -15,634	-20%	-$187K	0.05%	137
2024 Q3	$975K	Sell	76,799 -3,130	-4%	-$46.5K	0.09%	111
2024 Q2	$1.34M	Buy	79,929 +18,725	+31%	+$266K	0.13%	101
2024 Q1	$918K	Buy	+61,204	New	+$1M	0.09%	121

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Oak Ridge Investments's URGN Position: Q2 2026 in Review

Oak Ridge Investments increased its UroGen Pharma (URGN) stake by 2.5% in Q2 2026, buying an estimated $59.3K and bringing the position to 88,591 shares worth $3.26M. The position accounts for 0.18% of the portfolio, ranked #82.

Oak Ridge Investments first reported a position in URGN in Q1 2024 and has held it in 10 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Oak Ridge Investments held 88,591 shares of UroGen Pharma worth $3.26M as of Q2 2026.
Oak Ridge Investments bought 2,188 UroGen Pharma shares in Q2 2026, an estimated $59.3K.
UroGen Pharma made up 0.18% of Oak Ridge Investments's portfolio in Q2 2026, its #82 holding.
Oak Ridge Investments first reported a position in UroGen Pharma in Q1 2024 and has held it in 10 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Oak Ridge Investments's 13F filing for Q2 2026, filed 21 Jul 2026.